AstraZeneca is reportedly in discussions to merge with U.S.-based rival Bristol Myers Squibb, eyeing a deal that would create a pharmaceutical powerhouse valued at around $400 billion. The talks, revealed by the Financial Times, have been ongoing for several months, although it remains uncertain if the companies will finalize the agreement. Such a merger would rank among the largest in industry history, reshaping the competitive landscape of the healthcare sector.

Bristol Myers Squibb has established itself as a significant player in cancer treatment, largely due to an aggressive acquisition strategy that included the recent purchase of Medarex. This acquisition brought a promising drug targeting metastatic melanoma, which is also being tested in late-stage trials for lung and prostate cancers. Along with a strong cancer drug portfolio including Erbitux, Ixempra, and Taxol, Bristol Myers Squibb brings substantial therapeutic assets to the potential merger.

AstraZeneca’s growth has similarly been fueled by its focus on oncology and rare diseases, contributing to robust second-quarter sales results. The company reported roughly $25 billion from cancer therapies in 2025, making up nearly half of its total revenue. AstraZeneca has also been expanding its presence in the U.S. market, notably by planning a direct U.S. listing last year to capitalize on favorable valuation conditions while maintaining its London listing.

This reported merger emerges about 12 years after AstraZeneca successfully resisted a takeover attempt by Pfizer, marking a significant moment in its corporate history. Both companies have not commented publicly on the deal, leaving the market to speculate on the potential impact. If completed, the combination of AstraZeneca and Bristol Myers Squibb would create a dominant force in pharmaceuticals with a broad portfolio and significant financial scale.